Human Immunodeficiency Virus Therapeutics Market – By Drug Type, By Drug Class, By Distribution Channel & Global Forecast, 2025 – 2034

Human Immunodeficiency Virus Therapeutics Market Size

The global human immunodeficiency virus therapeutics market size valued at USD 39 billion in 2024 and is projected to exhibit 3.5% CAGR from 2025 - 2034. The revenue growth in this market can be attributed to the high HIV infection prevalence, availability of new treatment options, rise in based initiatives and programs, and positive regulatory approvals.
 

U.S. FDA, and other bodies, has started authorising use of modern HIV medications, including ones meant for difficult to treat individuals. These alternatives cater to patients who face difficulties with daily doses in oral form. For instance, the U.S FDA has had the needs of patients who have human immunodeficiency virus type one, whereby their infection cannot be treated, tolerated or even safe with other available drugs, in mind. The Authority approved Sunlenca (lenacapavir) a new anti-retro viral medication in December 2022.

Human immunodeficiency virus therapeutics include medication to control and contain the disease. Protective mechanisms against the virus include antiretroviral drugs, which reduce the formation of viruses, helping delay one getting to the AIDS stage. Primary goals include having the viral loads at low undetectable levels, eliminating the chances of transmission, while ensuring there is a robust immune system.
 

Human Immunodeficiency Virus Therapeutics Market Trends

• Therapies, such as cabotegravir/rilpivirine, enhance patient adherence and reduce the burden caused by having to take oral medication daily with the use of long acting injectables. As a result, a shift towards more patient-friendly and easy treatment options is encouraged as injectables become successful. Also, the availability of the injectable treatments has increased with them switching to a monthly or bi-monthly dosing schedule.
   
• The provision of Pre-Exposure Prophylaxis and the achievement of an HIV diagnosis have become the primary tools of HIV prevention. The problem of new infections/AIDS is much less severe than in societies with a high population of HIV patients due to their willingness to promote PrEP more actively to potential candidates.
   
• HIV management is now more effective with the use of new medications that combine 2 or 3 HIV drugs in one single tablet, compared to previously when a patient used to take several pills. Patients can adhere to their medications, remember to take them, and have greatly simplified plans in place.
   
• Tools that are powered by AI and digital technologies are helping to predict treatment outcomes, observe patient compliance, and provide up-to-date information to hospitals and clinicians. Most importantly, these technologies are currently being employed to assist patients to recover from HIV and to monitor their HIV treatment programs.
   

Human Immunodeficiency Virus Therapeutics Market Analysis

Based on drug type, the market is segmented into branded drugs and generic drugs. Branded drugs dominate the market with a share of 74.5% in 2024.
 

• Increasing prescriptions for fixed dose combinations such as Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide), Genvoya (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide), and Triumeq (abacavir, dolutegravir, and lamivudine) are contributing to the revenue growth in the segment.
   
• Patented medicines and fixtures combined have substantially increased the sales of this segment due to an increase in prescriptions for the drugs. Recently, these drugs have witnessed a surge in prescribing as they possess proven effectiveness, have been in extensive clinical practice, and the role they play in combination therapies provides for streamlined dosing and better outcomes for the patients.
   
• On the other hand, newer brands of drugs, such as those of the integrase inhibitors classes, tend to have a higher efficacy and a safety profile, thus replacing older drugs in the market and increasing the demand for such branded medicines.
   
• Drug manufacturers are constantly coming up with new combinations or alternatives of various antiretroviral drugs to streamline the treatment regimens and, as a result, aid with better patient interactions and adherence. As a result, this too fostered the growth in sales of branded drugs.
   

Based on drug class, the human immunodeficiency virus therapeutics market is segmented into nucleoside-analog reverse transcriptase inhibitors, integrase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, entry, and fusion inhibitors, and coreceptor antagonists. The nucleoside-analog reverse transcriptase inhibitors segment held a dominating share of 41.2% in the market in 2024.
 

• The most prevalent and well-researched class of HIV drugs is represented by nucleoside-analog reverse transcriptase inhibitors. Their clinical use has also shown that they are effective in blocking the action of reverse transcriptase, an important enzyme for the life cycle of the HIV virus. Lamivudine, zidovudine, and tenofovir are examples of nucleoside-analog reverse transcriptase inhibitors that are important components of combination therapy in the first line.
   
• It’s also worth noticing that nucleoside-analog reverse transcriptase inhibitors, like tenofovir, play a critical role in improving adherence to PrEP in HIV-negative users and thus reducing the chances of getting infected. Their performance in the treatment of HIV-infected people and the prevention of HIV growth in non-infected subjects strengthens their share across the market.

Based on distribution channel, the human immunodeficiency virus therapeutics market is segmented into hospital pharmacies, drugs stores and retail pharmacies, and online pharmacies. The hospital pharmacies segment dominated the market with a share of about 47.4% in the year 2024.
 

• Hospital pharmacies store a wide range of HIV drugs, not found in retail outlets, such as injectables or antiretrovirals that are currently available only on limited release. These include long acting injectables and combination therapies that must be administered with careful attention by trained personnel.
   
• People who are in the later stages of HIV disease or have a more complicated treatment history, for example, those who display resistance to medication, are invariably treated at a hospital. These people need more aggressive therapy, which requires the use of hospitals rather than local drug stores. Hence, there is a greater volume of prescriptions for specialized HIV formulations in the hospitals than in the pharmacies.

In 2024, the U.S. led the North American human immunodeficiency virus therapeutics market, generating a revenue of about USD 14.5 billion.
 

• As per the latest report by the Centers for Disease Control and Prevention, about 31,800 individuals were estimated to have newly diagnosed HIV in the U.S. in 2022. The reduction in HIV infections in the United States between 2018 and 2022 is likely to be around 12%, and it can be explained by the increase in PrEP prescriptions, a greater proportion of people with controlled viral load, and more people getting tested for HIV. The increase in PrEP therapeutic prescriptions is significantly contributing to revenue growth in the U.S.
   
• In addition, the U.S. is one of the countries with the most developed healthcare systems when compared to other countries and provides adequate access to specialized services for individuals with HIV, which include the latest antiretroviral therapies, and innovative long-acting injectables.
   
• Additionally, in the U.S., there is quite considerable access to health insurance, as well as government-sponsored Medicaid and Medicare programs, which allow more patients to be treated with lifesaving HIV therapies. The existence of a widespread network of pharmacies operating in retail and hospitals, as well as web-based pharmacies, enables greater availability of treatment to the population, thereby enhancing the revenue growth.
   

The UK is set to see a robust expansion in its human immunodeficiency virus therapeutics market from 2025 to 2034.
 

• Increasing awareness, which is reducing the stigma concerning the disease, together with the initiation of regular testing for HIV infections in the UK, has been made possible by the combination of public health campaigns and government policy measures. Such in regard is the British HIV Association (BHIVA), whose responsibility is to educate the population, especially people at risk of HIV infection and healthcare workers, about HIV to ensure high rates of early diagnosis and treatment.
   
• Additionally, subjects in the UK are amongst the rapid adopters of long-acting injectables and fixed-dose combination treatments. Easy availability has guaranteed that people living with HIV in the UK are treated with the latest highly effective therapies with improved adherence and viral suppression rates. Availability and increasing use of new treatment regimens are aiding revenue growth in the UK.
   

Japan's human immunodeficiency virus therapeutics market is set for lucrative growth from 2024 to 2034.
 

• There is strong support by the Japanese government about the HIV/AIDS pandemic and the treatment initiatives as part of the public health services that have influenced the market.
   
• Initiatives such as free testing for HIV/AIDS as part of the National AIDS Prevention Program and free provision of antiretroviral therapy to the nationals have greatly lowered the prevalence rate of HIV infection. These initiatives, in addition, have ensured that those who have been diagnosed with HIV have been able to gain access to treatment, enhancing revenue for the market.
   
• Moreover, Japan's progressed healthcare gives every HIV patient ready and beneficial treatment. Extending access to the latest diagnostic technologies, modern treatment facilities, and highly qualified personnel helps to increase Japan's position in the management of chronic diseases, including HIV.
   

Saudi Arabia's human immunodeficiency virus therapeutics market is expected to witness substantial growth during the forecast period.
 

• Relating to the treatment of HIV/AIDS people, the government of Saudi Arabia has taken measures on public health campaigns targeting the broader public with the aim of increasing awareness of HIV transmission and prevention.
   
• The government of Saudi Arabia issued last December 2023 an application of the Saudi Initiative to Combat AIDS in participating GCC Countries with the intention of strengthening the HIV-combating health support services in the Gulf.
   
• These kinds of initiatives put in place by the government are expected to increase HIV-related awareness, which in turn will lead to an increase in the Saudi Arabia market size.
   

Human Immunodeficiency Virus Therapeutics Market Share

The worldwide market for human immunodeficiency virus therapeutics manages to be moderately fragmented with the key players having an edge in the market. Vendors like Gilead Sciences, ViiV Healthcare and Bristol Myers Squibb are dominating the market with robust presence owing to their superior products including Truvada, Dolutegravir and Isentress. But the emergence of new competitors and generics has led to a competitive multi-tiered landscape. Lower tier players are increasingly carving out a market presence by targeting specific patient needs like treating resistant strains or by just selling it cheaper.
 

HIV Therapeutics Market Companies

Some of the eminent market participants operating in the human immunodeficiency virus therapeutics industry include:

• AbbVie
• Aurobindo Pharma
• Boehringer Ingelheim International GmbH
• Bristol-Myers Squibb Company
• Cipla
• Dr. Reddy's Laboratories
• F. Hoffmann-La Roche
• Gilead Sciences
• Hetero Drugs
• Johnson & Johnson
• Merck & Co
• Mylan N.V. (Viatris)
• Sun Pharmaceutical Industries
• Teva Pharmaceutical Industries
• ViiV Healthcare
   

USP For the Top Players:

• Broad portfolio covering HIV prevention, treatment, and long-acting formulations.
   
• Extensive global reach with licensing agreements for generic distribution.
   
• Collaborative research partnerships with global institutions and pharmaceutical companies.
   

Human Immunodeficiency Virus Therapeutics Industry News:

• In October 2024, Gilead Sciences, Inc. announced collaboration with six generic drug manufacturers, Dr. Reddy's Laboratories, Emcure Pharmaceuticals, Hetero Labs, Mylan (Viatris), Eva Pharma, and Ferozsons Laboratories, to grant royalty-free licenses to produce and distribute more affordable versions of its HIV prevention drug lenacapavir, across 120 low and lower-middle income countries.
   
• In June 2022, Cipla announced the South African Health Products Regulatory Authority (SAHPRA) approval of its innovative, sweet-tasting, heat-stable '4-in-1' fixed-dose combination of antiretroviral drugs. This formulation, specifically designed for infants and young children with HIV, comprises abacavir, lamivudine, lopinavir, and ritonavir.
   

The human immunodeficiency virus therapeutics market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Drug Type

• Branded drugs
• Generic drugs

Market, By Drug Class

• Nucleoside-analog reverse transcriptase inhibitors
• Integrase inhibitors
• Non-nucleoside reverse transcriptase inhibitors
• Protease inhibitors
• Entry and fusion inhibitors
• Coreceptor antagonists

Market, By Distribution Channel

• Hospital pharmacies
• Drugs stores and retail pharmacies
• Online pharmacies

The above information is provided for the following regions and countries:

• North America 
  • U.S.
  • Canada
• Europe 
  • Germany
  • UK
  • France
  • Spain
  • Italy 
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea 
• Latin America
  • Brazil
  • Mexico
  • Argentina 
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE